Elsevier

Annals of Oncology

Volume 32, Supplement 5, September 2021, Pages S1287-S1288
Annals of Oncology

Breast cancer, metastatic
LBA1 Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (Pts) with HER2+ metastatic breast cancer (mBC): Results of the randomized phase III DESTINY-Breast03 study

https://doi.org/10.1016/j.annonc.2021.08.2087Get rights and content
Under an Elsevier user license
open archive

Cited by (0)